About 60–80% of breast cancers arising in carriers of constitutional BRCA1 mutations show triple‐negative phenotype, whereas the rate of TNBC in BRCA2 carriers is closer to that observed in the general population 13, 14. This evidence concerns the gene BRCA2 and breast cancer.